Table 2. Predicted warfarin dose in mg/day and 95% confidence intervals (95%CI) based on CYP4F2 genotypes.
| CYP4F2 *1/*1 | CYP4F2 *1/*3 | CYP4F2 *1/*3 | |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Total | N | Dose (95%CI) | N | Dose (95%CI) | N | Dose (95%CI) | |
| All | 1238 | 784 | 4.9 (4.8 – 5.1) | 390 | 5.1 (4.9 – 5.3) | 64 | 5.5 (5.1 – 6.0) |
| European Americans | 707 | 340 | 4.4 (4.3 – 4.6) | 305 | 4.6 (4.5 – 4.8) | 62 | 5.0 (4.6 – 5.5) |
| African Americans | 531 | 444 | 5.7 (5.5 – 5.9) | 85 | 5.7 (5.3 – 6.2) | 2 | 6.8 (4.3 – 10.9) |
a
Adjusted for age (centered at 40 years); body surface area (BSA) centered at 2.01, chronic kidney disease (CKD), amiodarone therapy, CYP2C9*2, CYP2C9*3, CYP2C9*5, *6 and *11 together, VKORC1, and rs12777823 variants. CKD was based on the Modification of Diet in Renal Disease Study equation. Patients were categorized into 3 categories: eGFR ≥60 (no CKD or mild CKD stage 1 and 2), eGFR=30-59 (moderate CKD; stage 3) and eGFR < 30 (severe CKD; stage 4 and 5). CYP2C9*2, CYP2C9*3, and VKORC1 were included as additive; 0 if no variants; 1 if heterozygous and 2 if homozygous for the variant allele. CYP2C9*5, *6 and *11 together, and rs12777823 were categorized as 0 if no variants and 1 if heterozygous or homozygous for the variant allele.